Multiple thyroid disorders and risk of osteoporosis: a two-sample Mendelian randomization study.
1/5 보강
[INTRODUCTION] Previous research has demonstrated that even minor changes in thyroid function are associated with an increased risk of osteoporosis (OP).
- 95% CI 1.023-1.194
- OR 1.105
- 연구 설계 meta-analysis
APA
Shi G, Lin Z, et al. (2025). Multiple thyroid disorders and risk of osteoporosis: a two-sample Mendelian randomization study.. Journal of bone and mineral metabolism, 43(2), 96-107. https://doi.org/10.1007/s00774-024-01559-7
MLA
Shi G, et al.. "Multiple thyroid disorders and risk of osteoporosis: a two-sample Mendelian randomization study.." Journal of bone and mineral metabolism, vol. 43, no. 2, 2025, pp. 96-107.
PMID
39641795
Abstract
[INTRODUCTION] Previous research has demonstrated that even minor changes in thyroid function are associated with an increased risk of osteoporosis (OP). However, the causal relationship between thyroid disorders and the development of OP remains unclear. To address this, we aim to investigate the connection between genetic predispositions to various thyroid disorders and OP using a two-sample Mendelian randomization (MR) approach.
[MATERIALS AND METHODS] Instrumental variables (IVs) for multiple thyroid disorders were sourced from a large genome-wide association study (GWAS) meta-analysis dataset. Summary-level data for OP were obtained from the FinnGen consortium. Inverse variance weighting (IVW) methods served as the primary approach for MR analysis. Sensitivity analyses included MR-Egger regression, heterogeneity testing, multiple validity tests, and leaFve-one-out sensitivity tests.
[RESULTS] IVW analysis revealed a direct causal effect of hypothyroidism (OR = 1.105, 95% CI 1.023-1.194, P 0.011) and Hashimoto's thyroiditis (OR = 1.142, 95% CI 1.026-1.271, P 0.015) on OP. However, no direct causal association was found between hyperthyroidism (OR = 1.030, 95% CI 0.944-1.123, P 0.508) or thyroid cancer (OR = 0.971, 95% CI 0.898-1.051, P 0.469) and OP.
[CONCLUSION] Our MR analysis revealed a causal association between hypothyroidism, Hashimoto's thyroiditis, and OP. This highlights the significant impact of thyroid function on bone health. However, further longitudinal studies are needed to confirm these findings conclusively.
[MATERIALS AND METHODS] Instrumental variables (IVs) for multiple thyroid disorders were sourced from a large genome-wide association study (GWAS) meta-analysis dataset. Summary-level data for OP were obtained from the FinnGen consortium. Inverse variance weighting (IVW) methods served as the primary approach for MR analysis. Sensitivity analyses included MR-Egger regression, heterogeneity testing, multiple validity tests, and leaFve-one-out sensitivity tests.
[RESULTS] IVW analysis revealed a direct causal effect of hypothyroidism (OR = 1.105, 95% CI 1.023-1.194, P 0.011) and Hashimoto's thyroiditis (OR = 1.142, 95% CI 1.026-1.271, P 0.015) on OP. However, no direct causal association was found between hyperthyroidism (OR = 1.030, 95% CI 0.944-1.123, P 0.508) or thyroid cancer (OR = 0.971, 95% CI 0.898-1.051, P 0.469) and OP.
[CONCLUSION] Our MR analysis revealed a causal association between hypothyroidism, Hashimoto's thyroiditis, and OP. This highlights the significant impact of thyroid function on bone health. However, further longitudinal studies are needed to confirm these findings conclusively.
MeSH Terms
Humans; Mendelian Randomization Analysis; Osteoporosis; Thyroid Diseases; Genome-Wide Association Study; Risk Factors; Genetic Predisposition to Disease
같은 제1저자의 인용 많은 논문 (5)
- CD48 is a novel immune checkpoint on tumour-associated macrophages in hepatocellular carcinoma.
- B-Lymphoblastic Lymphoma Presenting With a Facial Mass as the Initial Symptom.
- GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma.
- TRIB1 facilitates the proliferation and migration of ovarian cancer cells by inducing EMT progression.
- Potential anti-gastric cancer properties of modified Lichong decoction based on metabolomics, network pharmacology, and pharmacological verification.